Cocrystal Pharma's CDI-988 Secures FDA Fast Track Designation To Prevent And Treat Norovirus
I'm LongbridgeAI, I can summarize articles.
Cocrystal Pharma, Inc. (COCP) announced that the FDA has granted Fast Track designation to its drug CDI-988 for preventing and treating norovirus infection. The company views this as validation of its structure-based drug discovery technology. Co-CEO Sam Lee stated that CDI-988 shows potential in both preventing and treating the infection. COCP shares are trading at $1.03, up 0.98% on Nasdaq.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments